| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss before income tax | -7,024 | -14,616 | -12,887 | -15,001 |
| Income tax benefit | 0 | 0 | - | - |
| Net loss | -7,024 | -14,616 | -12,887 | -15,001 |
| Other comprehensive income/(loss) - foreign currency translation adjustments, net of tax | -2,267 | 6,647 | 3,559 | 7,174 |
| Total comprehensive loss | -9,291 | -7,969 | -9,328 | -7,827 |
| Earnings per share, basic | -0.01 | -0.02 | -0.02 | -0.02 |
| Earnings per share, diluted | -0.01 | -0.02 | -0.02 | -0.02 |
| Weighted average number of shares outstanding, basic | 799,947,013 | 799,435,329 | 784,279,387 | 770,146,589 |
| Weighted average number of shares outstanding, diluted | 799,947,013 | 799,435,329 | 784,279,387 | 770,146,589 |
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)